Since May 2022, RSEA’s research partner, Zhittya, has been conducting Medical Research Studies with patients suffering with Parkinson’s disease, progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA). These Medical Research Studies have taken place in the British Virgin Islands (BVI) where clearance has been granted to conduct those trials. The first human data (91 patients as of Sep 2023) from Parkinson's disease medical research studies conducted in the BVI have shown the medicine to be completely safe and well tolerated. Regarding efficacy, the medicine resulted in motor score improvements in the patients of 18% to 82% which is a very positive and significant result. It is estimated that the world has 30 million Parkinson’s disease sufferers. RSEA believes over half are in the region surrounding RSEA.

The other brain disorders, including stroke recovery, Alzheimer’s disease, dementia, multiple sclerosis, traumatic brain injuries, MSA and PSP are all additional opportunities.

Here is a link to a YouTube webinar on the improvement in the first human Parkinson’s disease sufferers.

Heart disease is the #1 cause of death in the world. It is estimated that over 18 million people died of heart disease in 2021. Of that, over 9 million were in Southeast Asia or in the surrounding area. China had the highest number of heart disease deaths last year, followed by India, Russia, the United States and Indonesia. Three of those five nations are in Southeast Asia or in proximity.

The medicine that Zhittya is developing for RSEA, FGF-1, has been utilized in four separate human heart trials. To date, there have been no adverse events and the improvement in patients’ hearts has been material. Here is a link to an ABC News broadcast about Zhittya’s medicine growing new blood vessels in the human heart. After new blood vessel growth, angina pain was eliminated and heart function was enhanced. 

The approval of the heart medicine in the US could be several years away; however, Zhittya is in discussions with clinics in Malaysia, Brunei, and Vietnam about providing the medicine to desperate heart patients through Medical Research Studies in those nations.

The Voyin anti-cancer particle is the only medicine that Zhittya is developing which is not based upon the FGF-1 molecule. The drug is based on AAV (adeno-associated virus). Zhittya started this project in 2022, after studying it for over 12 years, and has now completed its animal development studies and plans in 2024 to dose its first human test subjects with its Voyin particle. 

The Voyin anti-cancer particle attacks unique surface markers that are only exposed on endothelial cells, which exist inside the blood vessels in malignant tumors. Through the action of the Voyin particle attacking and killing those endothelial cells, the vascular system within the tumor dies, leading to an eradication of the malignant tumors due to a lack of blood flow to feed the tumor cells. In dogs, which had naturally occurred malignant tumors, a similar particle eradicated 95% of the tumor within 60 days.

It is estimated that 14 million people died of cancer in 2020. Half of those people are in the RSEA region, or around 7 million people. Voyin only works on solid tumors, which is about 90% of all cancers. This represents a possible 6.3 million patients in the RSEA territory.

Zhittya’s drug for wound healing has shown very positive in four previous trials on healing chronic diabetic foot ulcers. The drug has also been used for venous ulcers and we believe that it would work in many situations in which wound healing is needed such as burns, bed sores and more. 

As of September 22, 2023, Zhittya is working on medicines which address 20
medical indications. Of those 20 medical indications, Zhittya believes that 14
address diseases which presently have no satisfactory treatment options and are
referred to as “Unmet Medical Needs.”

• End-stage cancer
• Heart disease – so-called “no option” heart patients
• Stroke recovery
• Parkinson’s disease
• Alzheimer’s disease
• Amyotrophic lateral sclerosis (ALS)
• Chronic depression
• Multiple sclerosis (MS)
• Traumatic brain injury (TBI)
• Post-traumatic stress disorder (PTSD)
• Chronic traumatic encephalopathy (CTE)
• Vascular dementia
• Multiple systems atrophy (MSA)
• Peripheral artery disease (PAD)
• Diabetic foot ulcers (DFUs)
• Venous ulcers
• Pressure wounds (bed sores)
• Surgical wounds
• Burns
• Male pattern baldness